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Effects of magnolol on UVB-induced skin cancer
development in mice and its possible mechanism
of action
Chandeshwari Chilampalli1, Ruth Guillermo1, Xiaoying Zhang2, Radhey S Kaushik3,4, Alan Young4, David Zeman4,
Michael B Hildreth3, Hesham Fahmy1 and Chandradhar Dwivedi1*
Abstract
Background: Magnolol, a plant lignan isolated from the bark and seed cones of Magnolia officinalis, has been
shown to have chemopreventive effects on chemically-induced skin cancer development. The objectives of this
investigation are to study the anticarcinogenic effects of magnolol on UVB-induced skin tumor development in
SKH-1 mice, a model relevant to humans, and determine the possible role of apoptosis and cell cycle arrest
involved in the skin tumor development.
Methods: UVB-induced skin carcinogenesis model in SKH-1 mice was used for determining the preventive effects
of magnolol on skin cancer development. Western blottings and flow cytometric analysis were used to study the
effects of magnolol on apoptosis and cell cycle.
Results: Magnolol pretreated groups (30, 60 μ g) before UVB treatments (30 mJ/cm2, 5 days/week) resulted in 27-
55% reduction in tumor multiplicity as compared to control group in SKH-1 mice. Magnolol pretreatment increased
the cleavage of caspase-8 and poly-(-ADP-ribose) polymerase (PARP), increased the expression of p21, a cell cycle
inhibitor, and decreased the expression of proteins involved in the G2/M phase of cell cycle in skin samples from
SKH-1 mice.
Treatment of A431 cells with magnolol decreased cell viability and cell proliferation in a concentration dependent
manner. Magnolol induced G2/M phase cell cycle arrest in A431 cells at 12 h with a decreased expression of cell
cycle proteins such as cyclin B1, cyclin A, CDK4, Cdc2 and simultaneous increase in the expression of Cip/p21, a
cyclin-dependent kinase inhibitor. Magnolol induced apoptosis in vivo and in vitro with an increased cleavage of
caspase-8 and PARP. Phospho-signal transducers and activators of transcription 3 (Tyr705), B-Raf, p-MEK, and p-AKT
were down-regulated, whereas phosphorylation of ERK was induced by magnolol in A431 cells.
Conclusions: Magnolol pretreatments prevent UVB-induced skin cancer development by enhancing apoptosis,
causing cell cycle arrest at G2/M phase, and affecting various signaling pathways. Magnolol could be a potentially
safe and potent anticarcinogenic agent against skin cancer.
Background
In the United States, human, non-melanoma skin cancers
are most frequently diagnosed in Caucasians, accounting
for over 3.5 million cases each year [1]. American Cancer
Society estimates indicated 11,980 deaths from skin can-
cer in 2011 [2]. The major causative factor for skin
cancer is UV radiation from sunlight [3,4]. Both experi-
mental and epidemiological evidences suggest UVB is an
important component of solar radiation that acts as a
complete carcinogen by initiating and promoting skin
cancer [5,6]. Estimates show that one among five Ameri-
cans will develop skin cancer [7]. UV radiation, besides
resulting in characteristic DNA damage, also causes
tumor promotion by inducing various signal transduction
pathways which can lead to distinct cellular responses
including cell proliferation, transformation, and cell
* Correspondence: Chandradhar.Dwivedi@sdstate.edu
1Department of Pharmaceutical Sciences, South Dakota State University,
Brookings, SD 57007, USA
Full list of author information is available at the end of the article
Chilampalli et al. BMC Cancer 2011, 11:456
http://www.biomedcentral.com/1471-2407/11/456
© 2011 Chilampalli et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
death [8,9]. Mechanisms that suppress tumorigenesis
involve the modulation of signal transduction pathways
leading to arrest in the cell cycle progression or induction
of apoptosis. It has been proposed that sunscreens alone
are not sufficient in preventing skin cancer, thus there is
a need for more effective ways to prevent this malignancy
[10,11]. For this reason, chemoprevention of skin cancer
by natural compounds has gained importance in recent
years [12,13]. More than 1000 phytochemicals have
shown chemopreventive effects against cancer [14-16],
and one such phytochemical is magnolol, whose effects
are investigated for the prevention of skin cancer in this
study.
Magnolol and honokiol are phenolic compounds
obtained from the bark and seed cones of Magnolia offi-
cinalis which has been used in traditional Chinese medi-
cine. Recently, we have reported the chemopreventive
effects of honokiol on UVB-induced skin cancer develop-
ment in mice [17]. Honokiol and magnolol are isomers
and share a number of biological properties. Studies have
demonstrated that magnolol has multiple pharmacologi-
cal properties such as antioxidant [18], anti-inflammatory
[19], and central nervous system depressant effects [20].
It has been reported that magnolol delayed the formation
of papillomas in mouse skin initiated by 7,12-dimethyl-
benz (a) anthracene (DMBA) and promoted by 12-O-tet-
radecanoyl phorbol-13-acetate (TPA) [21].
For the first time, in this study, we reported the effects
of magnolol on UVB-induced skin cancer development
in SKH-1 mice. Since UVB induces squamous cell carci-
noma in mice, the effects of magnolol on human epider-
moid squamous cell carcinoma A431 cells were
investigated to elucidate the possible mechanisms of
action. The effects of magnolol were investigated on
UVB-induced skin carcinogenesis in SKH-1 mice, a
model relevant to human cancer where UVB acts as
complete carcinogen. Loss of apoptosis and rapid cell
proliferation are major factors responsible for tumori-
genesis [22], therefore, the present study focuses on the
effects of magnolol on apoptosis, cell survival pathways
and cell cycle arrest.
Signal transduction and activators of transcription 3
(STAT 3) and mitogen-activated protein kinase (MAPK)
signaling play a major role in apoptosis, proliferation,
and tumor promotion [23,24]. Overactivity of the
MAPK pathway has been shown to be involved in can-
cer promotion and development [25-27]. Therefore, we
investigated the effects of magnolol on the modulation
of STAT3 and MAPK signaling pathways.
Methods
Reagents
Magnolol was purchased from Nacalai tesque (Kyoto,
Japan). Thiazolyl blue tetrazolium bromide (MTT) and
other chemicals of analytical grade were purchased from
Sigma Chemical Co. (St. Louis, MO). Cell proliferation
ELISA kit was purchased from Roche Diagnostics
GmbH (Mannheim, Germany). Vibrant Apoptosis Kit 2
and APO-BrdU TUNEL assay kit were purchased from
Molecular Probes (Eugene, OR). The primary antibodies
such as cleaved caspase-3, cleaved caspase-8, pSTAT3-
Tyr705, pSTAT3-Ser445, pMEK1/2, B-Raf and cleaved
PARP were purchased from Cell Signaling Technology
(Beverly, MA). Primary Antibodies such as Cdc25A,
Cdc25B, Cdc25C, p-Cdc25C, CDK-2, CDK-4, Cyclin B1,
Cyclin A, Cdc2p34, p-ERK1/2, p-AKT, PCNA, anti-
mouse IgG horseradish peroxidase-linked and anti-rab-
bit IgG horseradish peroxidase-linked secondary antibo-
dies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-Kip1/p27 antibody was pur-
chased from BD-Pharmingen (San Diego, CA) and anti-
Cip1/p21 antibody from Upstate Biotechnology (Lake
Placid, NY).
Cell culture
Human epidermoid carcinoma A431 cells were pur-
chased from American Type Culture Collection (Mana-
ssas, VA). A431 cells were cultured in DMEM
supplemented with 10% heat inactivated fetal bovine
serum, 100 unit/ml of penicillin and 100 ug/ml of strep-
tomycin in a humidified atmosphere containing 95% air
and 5% CO2 at 37°C. For treatments of cell cultures,
magnolol was dissolved in DMSO to make a 50 mM
stock solution, this stock solution was diluted in DMEM
at different concentrations and was immediately used. In
all assays the final concentration of DMSO in DMEM
was 0.4%.
Animals
Five to six week old female SKH-1 mice were purchased
from Charles River Laboratories (Wilmington, MA,
USA). Institutional Animal Care and Use Committee
(IACUC) approvals were obtained for all experimental
protocols. Mice were housed under climate-controlled
environment with a 12 hours light/dark cycle and were
provided with free access to food and water during the
experiment.
UVB Light Source
Four FS-40-T-12 UVB lamps were used as UVB light
source. UVB exposure dose was controlled by integrat-
ing dosimeters manufactured by Daavlin Corporation
(Bryan, OH, USA).
UVB-induced skin tumor development protocol
Five to six weeks old female SKH-1 mice were randomly
divided into four groups of 20 each. Carcinogenesis was
initiated and promoted by UVB, dose (30 mJ/cm2) for 5
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days a week (monday-friday). This is a dose close to the
UVB human exposure causing cancer development [28].
Group 1 served as control and received 200 μ l of acet-
one, group 2, group 3 and group 4 received 30 μ g, 45 μ
g and 60 μ g of magnolol in 200 μ l of acetone respec-
tively. Treatments were administered topically one hour
before UVB exposure. The experiment was carried out
for 25 weeks. Tumor counts and body weights were
recorded on weekly basis for 25 weeks. Results were
analyzed for tumor incidence, multiplicity and area.
Histopathological analysis of mice tumors
Mice were euthanized by cervical dislocation at the end
of the above mentioned protocol. Skin collected from
five animals per group was fixed by immersion in 10%
neutral buffered formalin for three days at room tem-
perature. Fixed tissues were processed into paraffin-wax
blocks, sectioned and stained with hematoxylin-eosin
(HE) and then evaluated under light microscope.
Effects of magnolol on tumor area in SKH-1 mice
Tumor areas were quantified as described earlier [17,29]
by using images from tumor bearing mice which were
taken at the end of 25 weeks. By using Photoshop CS3
(Adobe systems, San Jose, CA, USA) tumor boundaries
were determined and areas were measured by using
Image-Pro Plus 5.1 (Media Cybernetics, Inc, Bethesda,
MD, USA).
MTT assay for cell viability
A431 cells (9000 cells/well) were plated in 96 well
plates. After 24 h, cells were treated with different con-
centrations of magnolol (75, 100, 125 μM) for 12 h, 24
h and 48 h, using cells treated with growth medium
0.4% DMSO as control. Cell viability was determined at
the end of each treatment by using MTT assay as pre-
viously reported [30].
BrdU assay for cell proliferation
A431 cells (9000 cells/well) were plated in 96 well
plates. After 24 h, cells were treated with different con-
centrations of magnolol (75, 100, 125 μM) or treated
with growth medium 0.4% DMSO as control, for 48 h.
At the end of the treatment, Bromodeoxyuridine (BrdU)
incorporation assay was carried out using ELISA kit
(Roche Diagnostics, GmbH, Manheim, Germany) using
manufacturer protocol as previously reported from our
laboratory [30]. The experiment was repeated three
times.
Quantification of apoptosis by Annexin V/PI staining
Apoptosis was quantified by using Vibrant Apoptosis Kit
2 (Molecular Probes) as previously reported from our
laboratory [30]. A431 cells (2 × 105)/well were plated in
six well plates and after 24 h were treated with magnolol
(100, 150 μM) for 48 h. Then cells were collected,
washed and stained with annexin-V labeled with a fluor-
ophore that binds to phosphatidylserine exposed on
apoptotic cells. Also cells were treated with propidium
iodide (PI) a DNA intercalator dye that stains dead cells.
Samples were analyzed after staining with both dyes in
BD FACScan flow cytometry and the percentages of
apoptotic cells were evaluated using CellQuest software
(BD Biosciences, San Jose, CA).
Quantitation of DNA fragmentation by TUNEL assay
Apo-BrdU TUNEL assay kit (Molecular Probes) was
used to quantify the amount of DNA fragmentation in
magnolol treated A431 cells by using manufacturer’s
protocol as previously reported [30]. Positive and nega-
tive control cells were run with each assay.
Cell Cycle analysis
Subconfluent A431 cells plated in six well plates were
treated with different concentrations of magnolol (75,
100, 125 μM) or control media for 12, 24 and 48 h.
After each treatment, cells were harvested, washed and
fixed in 70% ethanol in DPBS. Fixed cells were treated
with 100 μ l of RNase A (1mg/ml) for 30 min at 37°C.
After incubation, 900 μ l of staining buffer and 20 μ l of
PI (Propidium iodide 1 mg/ml) were added to each sam-
ple and incubated for 30 min in the dark. The samples
were analyzed with BD FACScan flow cytometry (BD
Biosciences, San Jose, CA) using Cell Quest Software
(BD Biosciences, San Jose, CA) as previously reported
[31,32].
Preparation of tissues and cell lysates for immunoblotting
Tissue samples: Mice were sacrificed by cervical dislo-
cation, then treated skin was collected, fat from skin
was removed by scalpel, and then skin was homoge-
nized in 0.1 mM Tris-HCl/0.15 M NaCl (pH 7.4). The
homogenate was filtered and centrifuged at 10000g
for 45 min in a Beckman J2-21 centrifuge (Brea, CA.),
the obtained pellet was combined with 5% SDS, 0.5%
leupeptin and pepstatin and 1% PMSF, then was
passed through a 25G needle and centrifuged at
13000g for 20 min, the obtained supernatant was
heated for 5 min at 100°C. Finally, protein concentra-
tions were determined by BCA protein assay (Pierce,
Rockford, IL), then separated by SDS-PAGE and ana-
lyzed by Western blot.
For A431 cell lysates, 1.5 × 106 cells were plated in
100 mm culture dish. Subconfluent A431 cells were
treated with varying concentrations of magnolol (75,
100, 125 μM) and DMEM 0.4% DMSO as control, for
24 and 48h. At the end of each treatment cells were
lysed.
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Protein concentrations for tissues and cells’ proteins
were determined by BCA protein assay kit (Pierce,
Rockford, IL) with albumin as standard.
The tissues or cells’ proteins (50 μ g) were resolved by
SDS-PAGE and were transferred onto nitrocellulose
membranes. The membranes were probed with appro-
priate antibodies followed by secondary antibody and
detection by ECL plus detection system (Amersham
Biosciences, Piscataway, NJ). Equal protein loading is
ensured by reprobing each membrane with b-actin anti-
body. Western blotting was repeated for 3-5 samples
and representative bands from all replicated experiments
are reported. Western blots were detected and quanti-
fied by using a UVB Biochem Gel Documentation sys-
tem (UVP, Inc., Upland, CA) and this data were
analyzed statistically.
Statistical Analysis
INSTAT software (Graph Pad, San Diego, CA) was used
to analyze data. Chi square analysis was used for the
data on tumor incidence. Analysis of variance followed
by Tukey’s test was used for tumor multiplicity and
area, as well as for Western blots and for various in
vitro assays. Significance in all experiments was consid-
ered at p < 0.05. All values were expressed as mean ±
standard error.
Results
Effects of magnolol on weight gain and skin appearance
Pretreatment of animals with magnolol at all doses did
not have any effects on weight gain (data not shown)
and skin appearance of mice indicating the safety of
magnolol at these doses.
Chemopreventive effects of magnolol on UVB-induced
skin tumorigenesis
The effects of magnolol pretreatment on the tumor inci-
dence in SKH-1 mice are shown in Figure 1A. Tumor
incidence was 100% in both the control and magnolol
pretreated group (45 μ g) by the end of 25 weeks. Mag-
nolol pretreatments with 30 and 60 μ g per application
delayed the appearance of tumors as compared to con-
trol and 45 μ g magnolol applications. The results
showed that tumor incidence was significantly lower
during 21-25 weeks (p < 0.05) in the magnolol pre-
treated groups (30 and 60 μ g) as compared to control
group. Overall, the magnolol pretreatments (30, 60 μ g)
decreased tumor incidence compared with control at
the end of the experiment. Interestingly, 45 μ g applica-
tion of magnolol did not have any significant effect on
UVB-induced tumor incidence.
The effects of magnolol pretreatment on tumor multi-
plicity are shown in Figure 1B. Topical application of
30, 45, 60 μ g of magnolol prior to UVB treatments
showed protection against skin tumor development in
SKH-1 mice. We found that tumor multiplicity is signif-
icantly (p < 0.05) decreased in the magnolol pretreated
groups (30, 60 μ g) from 16 weeks to 25 weeks when
compared to control group. At the end of the experi-
ment, magnolol 30 μ g and 60 μ g pretreatments
resulted in 27-55% decrease in tumor multiplicity
respectively. Interestingly, the 45 μ g application of mag-
nolol had lesser effects than the 30 μ g application, simi-
lar to the results for tumor incidence.
The effects of magnolol pretreatment on the ratio of
total tumor area to total back area are shown in Figure
1C. In the control and magnolol pretreated groups (30,
45 and 60 μ g) the mean ratio of tumor area to total
back area was 4.5%, 0.5%, 0.5%, 0.3% respectively, result-
ing in 87 - 93% reduction in tumor area with magnolol
pretreatments compared to control. Unlike the data on
tumor incidence and multiplicity, effects of 45 μ g appli-
cation of magnolol had similar effects as 30 and 60 μ g
applications. A representative picture showing gross
appearance of the animals is shown in Figure 2.
The histopathological examination of the tumors after
25 weeks of treatments indicated that control and mag-
nolol treated groups developed squamous cell carcinoma
in the skin (Pictures not shown).
Effects of magnolol on apoptotic proteins in SKH-1 mice
Epidermal lysates from mice skin of both control and
magnolol pretreated groups were prepared at the end of
the study. The effects of magnolol on caspase-8 and
PARP cleavage, key proteins in apoptosis, are shown in
Figure 3A. Topical application of magnolol significantly
(p < 0.05) increased the cleavage of caspase-8 and PARP
as compared to control.
Effects of magnolol on cell cycle proteins in SKH-1 mice
Our studies on the effects of magnolol on human epi-
dermoid carcinoma A431 cells indicated that magnolol
caused cell cycle arrest at G2/M phase (results
reported later in the manuscript). Therefore, we inves-
tigated various proteins involved in G2/M phase of the
cell cycle in skin samples collected from the various
experimental groups. The effects of magnolol on cell
cycle proteins from skin of experimental mice are
shown in Figure 3B. Pretreatment of magnolol
decreased the expression of Cyclin B1, Cyclin A, CDK-
4 and Cdc25B but increased expression of Cdc2 and
Cdc25A as compared to control. Topical application of
magnolol to SKH-1 mice resulted in increased expres-
sion of the cell cycle inhibitor p21.
In order to further elucidate the mechanism of action
of magnolol, in vitro effects of various concentrations of
magnolol on human epidermoid carcinoma A431 cells
were investigated.
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Figure 1 Effects of magnolol pretreatment on tumor incidence, tumor multiplicity and tumor area in UVB-induced skin carcinogenesis
in SKH-1 mice. (A) Effects of topical magnolol pretreatment on tumor incidence. From the 20th week to the end of the experiment magnolol
30 μ g and 60 μ g reduced significantly tumor incidence. Each point represents the percentage of animals bearing at least one tumor, values
derived from 20 mice. *Significant difference (p < 0.05). (B) Effects of magnolol pretreatment on tumor multiplicity. Magnolol 30 and 60 μ g
pretreatment significantly decreased tumor multiplicities from the 16th to 25th week of UVB induced carcinogenesis. Each point represents mean
number of tumors per mouse ± SE derived from 20 mice. *Significant difference (p < 0.05). (C) Effects of magnolol treatment on tumor area.
Average ratio of total tumor area to total back area of the SKH-1 mice. Each bar represents mean ratio of tumor area per mouse ± SE derived
from 20 mice.* Significant difference (p < 0.05)
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Control group 
 
Magnolol 30 g 
 
Magnolol 45 g 
 
Magnolol 60 g 
 
Figure 2 Effects of magnolol treatment on UVB induced skin tumors in SKH-1 mice. Mice were exposed five days a week to 30 mJ/cm2
UVB one hour before different topical treatments. Control group (n = 20) was treated with 200 μ l of acetone. Treatment groups (n = 20 each)
received 30, 45 or 60 μ g of magnolol dissolved in 200 μ l of acetone. Pictures were taken at the end of the 25th week. Animals were randomly
chosen for the pictures.
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      Control                     30 g             45 g               60 g  Magnolol           
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        Cleaved Caspase-8  
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Cleaved PARP 
-Actin 
 
 
 
       Control                  30 g                  45 g                   60 g Magnolol  
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           Cyclin A 
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           p21  
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Figure 3 Effects of magnolol on the expression and activation of proteins in UVB-induced photocarcinogenesis in SKH-1 mice. (A)
Effects of magnolol on the cleavage of apoptotic proteins. Proteins were isolated from epidermal tissues of mice, lysates were prepared and
subjected to Western blot analysis. b-actin was used to verify equal loading of the samples for each membrane. Bands are representative from
three experiments. (B) Effects of magnolol pretreatment on the expression of cell cycle proteins. Proteins were extracted from the mice’s back
skin as mentioned in materials and methods. Lysates were subjected to Western blot analysis. b-actin was used as loading control. Bands are
representative from three experiments.
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Magnolol treatment decreased cell viability in A431 cells
As this is the first time the effects of magnolol on
human epidermoid carcinoma A431 cells are investi-
gated, MTT assay was conducted to determine the
effects of magnolol on cell viability. A431 cells double in
24 hours [33,34]; therefore we studied the effects of
magnolol treatment at 12, 24 and 48 hours. Magnolol
treatment (75-125 μM) showed a concentration and
time dependent decrease in cell viability Figure 4A.
Magnolol treatment did not show a significant effect at
12 h, but at 24h and 48 h treatment significantly
decreased cell viability. The effects of magnolol at 48h
may not be due to cell death but due to proliferation
inhibition. As shown in Figure 4A, cell viability of
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Figure 4 Effects of magnolol on cell viability and cell proliferation in A431 cells. (A) Effects of magnolol on cell viability. A431 cells were
treated with control media or magnolol (75-125 μM) for 12, 24 and 48 hours. At the end of the respective treatment MTT assay was performed.
Values are expressed as mean ± SE of eight replicates in each treatment. (B) Effects of magnolol on cell proliferation in A431 cells. Cells were
treated in similar conditions as described for MTT assay for 48 hours, and then BrdU incorporation assay was performed. Values are expressed as
mean ± SE of three replicates in each treatment.
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magnolol treated cells compared to controls ranged from
100-98% at 12h, 80-70% at 24 h and 80 - 50% at 48 h.
Magnolol inhibited cell proliferation in A431cells
We investigated the effects of magnolol on cell prolif-
eration in A431cells by BrdU incorporation assay. Mag-
nolol (75-125 μM) at 48 hours treatment resulted in a
30 - 96% decrease in cell proliferation as compared to
control. Figure 4B.
Magnolol induces apoptosis in A431 cells
To investigate whether cell death caused by magnolol is
an apoptotic response, cells were treated with magnolol
(100, 150 μM) for 48 h, followed by annexin-V/PI stain-
ing using a Vibrant Apoptosis kit. The stained cells
were analyzed through flow cytometry. As shown in Fig-
ure 5, early apoptotic cells are represented in the lower
right quadrant and late apoptotic cells in the upper
right quadrant. The results showed that magnolol treat-
ments (100 and 150 μM) resulted in 14.2% and 31.4% of
apoptosis respectively compared with DMEM 0.4%
DMSO treated control showing 8.8% of apoptotic cells.
These results suggest magnolol treatment induced a sig-
nificant degree of apoptosis (p < 0.05) in a concentra-
tion dependent manner. This data supports the results
from our animal experiments.
Magnolol induces DNA fragmentation in A431 cells
TUNEL assay was performed in order to investigate the
effects of magnolol on DNA fragmentation, which is
hallmark of late apoptosis that commits cells to die. As
shown in Figure 6A, M1 gate is used to indicate DNA
fragmented cells. Compared with the DMEM 0.4%
DMSO treated control showing 0.8% of DNA fragmen-
tation, magnolol treated A431 cells at 100 and 150 μM
resulted in 1.17% and 21% of DNA fragmentation after
48 hours treatment. These results suggest that 100 μM
did not induce DNA fragmentation whereas 150 μM
concentration significantly increased DNA fragmenta-
tion. Figure 6A.
       Control                                     100 M                               150 M            
0 
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40 
control 100 150 
%
 o
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pt
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 ce
lls
 
Concentration of magnolol in M  
*
Figure 5 Effects of magnolol on apoptosis in A431 cells as assessed by annexin-V/PI staining. Cells were treated with magnolol (0-150
μM) for 48 h, at the end of the treatment adherent and non-adherent cells were collected and treated with annexin-V labeled with a
fluorophore, which can identify apoptotic cells by binding to phosphatidylserine exposed on apoptotic cells; and with propidium iodide that
stained dead cells. Dot plot of annexin-V (FL1-H)/PI (FL2-H) staining of A431 cells by flow cytometry. The lower right quadrant shows early
apoptotic cells that are labeled with annexin-V, having green fluorescence. The upper right quadrant stained by annexin-V and PI indicates late
apoptotic cells. The lower left quadrant contains viable cells which exclude PI and are negative for annexin-V staining, and the upper left
quadrant are necrotic cells stained by PI only. The bar graph describes the percentages of apoptotic cells after each treatment. In each case data
represent mean ± SE of three observations. *p < 0.05 indicates statistical significant difference in magnolol treated groups compared with the
control.
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    - Actin 
      1          8        4.7      5.8       1      0.6     0.3      0.55 
         Cleaved PARP 
   - Actin 
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Figure 6 Effects of magnolol on DNA fragmentation and activation of apoptotic proteins in A431 cells. (A) DNA fragmentation. Cells
were treated with magnolol (0-150 μM) for 48 hours, at the end of the treatment, adherent and non-adherent cells were collected and
subjected to TUNEL assay. The gate M1 includes the apoptotic cells with fragmented DNA, which were positive for green fluorescence. The bar
graph indicates the percentages of apoptotic cells with fragmented DNA. In each case, data represents mean ± SE of three observations. *p <
0.05 indicates statistical significant difference in magnolol treated groups compared with the control. (B) Effects of magnolol on the activation of
apoptotic proteins in A431 cells. Cells were treated with magnolol for 24 and 48 h, cells were then collected. Cell lysates were prepared and
subjected to SDS-PAGE and Western blot analysis. Membranes were probed with appropriate antibodies. Pictures are representative from three
experiments.
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Magnolol induces cleavage of caspases and PARP during
apoptosis in A431 cells
Western blot analysis for caspases was used to further
investigate magnolol induced apoptosis in A431 cells.
The results showed that magnolol treatment increased
the expression of cleaved caspase-8, and cleaved cas-
pase-3 in a concentration dependent manner. We
observed increased cleavage of PARP only at 24 h,
membranes were checked for equal protein loading
using b-actin as control. Figure 6B.
Magnolol induces G2/M cell cycle arrest
To determine the mechanism involved in antiprolifera-
tive activity, the effects of magnolol on cell cycle pro-
gression were studied in A431 cells. The effects of
magnolol on the cell cycle were determined following
treatment with 75, 100 and 125 μM of magnolol for 12
h, 24 h, and 48 h. As shown in Figure 7A and 7B, mag-
nolol treatment resulted in a significantly increased
number of cells in G2/M phase following 12 h at 100
μM (33.45%) and 125 μM (45.79%) compared with the
control (22%). The concentration dependent effect of
magnolol on G2/M arrest is at the expense of the G0/
G1 phase (Figure 7B). These results are in agreement
with the data from animal experiments (Figure 3B).
Magnolol decreases expressions of G2/M regulatory
proteins Cdks and cyclins and increased Cip1/p21 in A431
cells
As cell cycle progression is dependent on various cyclins
and cyclin-dependent kinases (CDK’s), we focused our
interest on investigating the expression of A431cell cycle
proteins after magnolol treatment. Magnolol treatment
resulted in strong inhibition in the expression of cyclin
B1 (a protein involved in M phase) and cyclin A (a pro-
tein involved in both S and G2 phases) in a concentra-
tion and time dependent manner with almost
disappearance of bands with higher concentrations.
Magnolol treatment also decreased the expression of
CDK2 and CDK4 in a concentration dependent manner
at 24 h and 48 h. Reduction of CDK4 is more pro-
nounced than CDK2 (Figure 8)
To further elucidate the mechanisms involved in the
G2/M cell cycle arrest after magnolol treatment, we
investigated various proteins involved in the G2/M
phase. Magnolol treatment to A431 cells resulted in a
decreased expression of Cdc2p34, Cdc25A, Cdc25C and
pCdc25C (Ser216). All these results taken together sug-
gest that magnolol induces G2/M cell cycle arrest
through the modulation of G2/M regulatory proteins
(Figure 8).
We next assessed the effects of magnolol on the
expression of Cip1/p21, a cyclin dependent kinase inhi-
bitor which is known to regulate the cells at the G1-S
check point [35]. Magnolol treatment to A431 cells
resulted in a significant increase in the expression of
p21 in a concentration dependent manner compared
with control cells. Collectively all these results suggest
that increase in CDK inhibitory protein p21 by magnolol
may have a role in cell cycle arrest in G2/M phase of
A431 cells (Figure 8).
Magnolol inhibits STAT3 phosphorylation in A431 cells
In order to investigate the molecular mechanism of
magnolol in A431 cells, we first assessed the effects of
magnolol on STAT3 phosphorylation. The effects of
magnolol on STAT3 phosphorylation are shown in Fig-
ure 9. Compared with control treated cells, magnolol
treated cells showed inhibition of STAT3 phosphoryla-
tion at Tyr705 at 24 and 48 h, as well as inhibition of
phosphorylation of STAT3 at Ser 727 for 100 and 125
μM at 48 h. Magnolol treatment resulted in a time and
concentration dependent decrease in p-STAT3 Tyr705.
Downstream targets of STAT3 include PCNA and cyclin
D1 [24]. We found that magnolol treatment decreased
the expression of these proteins (Figure 9).
Effects of magnolol on B-Raf, p-MEK, ERK and AKT in
A431 cells
We next assessed the effects of magnolol on prolifera-
tion markers. MAPK signaling pathway play an impor-
tant role in cell proliferation, and cell growth arrest
[36]. We investigated the effects of magnolol on B-Raf,
p-MEK, p-ERK in A431 cells at 24 and 48 h. Results
showed that magnolol treatment decreased the expres-
sion levels of B-Raf and phosphorylation of MEK in a
concentration dependent manner (Figure 10). Our
results showed that ERK activation is increased for 125
μM at 24 and 48 h suggesting that magnolol induces
cell growth inhibition by activating ERK. In addition to
this, we found that magnolol treatment decreased the
phosphorylation of AKT.
Discussion
Magnolol, a hydroxylated biphenolic compound isolated
from Magnolia officinalis, most commonly used in tradi-
tional Chinese medicine has been investigated for its
effects on skin carcinogenesis. In this study, we deter-
mined the effect of magnolol in UVB-induced skin can-
cer in SKH-1 mice and on a human epidermoid skin
cancer cell line in vitro. Neolignans from Magnolia offi-
cinalis delayed papilloma formation in skin tumor pro-
motion by TPA [21,37]. We investigated the effects of
magnolol in a UVB-induced skin carcinogenesis model
with a UVB dose of 30 mJ/cm2/day which is more trans-
lational and relevant to human skin cancer as compared
to previous studies that used higher doses of UV radia-
tion [5,15]. Magnolol 30 μg and 60 μg in 200 μl of
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Figure 7 Effects of magnolol on the cell cycle phases distribution in A431 cells. (A) Cell cycle histograms. Cells were treated with
magnolol (0, 75, 100 and 125 μM) for 12 h. At the end of the treatment, cells were harvested and digested with RNase. Cellular DNA was
stained with propidium iodide and analyzed by flow cytometer as described in the Materials and Methods. (B) Data from the cell cycle
distribution histograms were summarized into a bar graph and presented as the mean ± SE of three observations. *p < 0.05 indicates statistical
significance in magnolol treated groups as compared to the control.
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acetone showed a protective effect in a dose dependent
manner when applied topically. In this study interest-
ingly, 45 μg magnolol did not have any effect on tumor
incidence and lower effects than the 30 μg application
in tumor multiplicity. Magnolol may have biphasic
effects on various target proteins not investigated in this
study, thus the middle dose is less effective than the
lower dose. Further studies with an increased range of
magnolol doses are needed to fully understand this
biphasic effect. We used very low doses (in micrograms)
of magnolol compared to other chemopreventive agents
which use milligrams per applications [5,13] thus indi-
cating the higher potency of magnolol over other agents.
The results demonstrated that magnolol delayed the
                 24 h                 48 h 
  Control     75      100      125     Control   75      100       125             Magnolol concentration in M 
        1         0.9      0.6      0.13         1        0.43     0.07    0.02  
       Cyclin B1 
       1         0.4       0.2         0           1         0.55    0.08         0     
       Cyclin A 
        1          0.84    0.6       0.37       1       1.34    0.91      0.4    
       CDK-2 
        1         0.84      0.86      0.35       1       0.72   0.59      0.25        
        CDK-4 
       1          0.7       0.68    0.58        1        1.06   0.45       0.22   
       Cdc2p34 
      1         0.74     0.66      0.5          1        1.1      0.86        0.3  
       Cdc25A            
       1    1.04   0.76     0.59       1       0.97     0.65      0.30      
       Cdc25 C 
       1          0.47    0.43      0.2        1        0.76     0.18       0.29 
       p-cdc25 C 
      1            5        8.6         5.8         1         4.5       9           7.15 
       p21 
       -Actin                                            
Figure 8 Effects of magnolol on the expression of cell cycle regulatory proteins in A431cells. Cells were treated with varying
concentrations of magnolol (0, 75, 100, 125 μM) for 24 and 48 h and thereafter cell lysates were prepared. Total cell lysates were subjected to
SDS-PAGE followed by Western blot analysis. b-actin was used to verify equal loading of samples
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onset of tumorigenesis when compared to the control.
Tumor multiplicity was reduced by 27-55% for 30 μg
and 60 μg of magnolol respectively compared to the
control.
Mechanistic studies showed that magnolol induced
apoptosis through extrinsic pathway and affected tumor
development by causing cell cycle arrest at G2/M phase
in our animal models.
To gain insight and have understanding of signaling
mechanisms involved in the magnolol anticarcinogenic
effect, we used human epidermoid A431 cells as an in
vitro model. Magnolol inhibits cell viability and prolif-
eration which together contributed to overall inhibition
of cell growth in A431 cells at concentrations 75-125
μM for 12-48 h. Cancer development involves deregula-
tion in cell cycle progression. Control of the cell cycle
plays an important role in controlling tumor growth
[22,38]. As such, effects of magnolol on the cell cycle
and its related proteins were investigated in A431 cells.
The results obtained demonstrate that magnolol induced
G2/M cell cycle arrest, is one mechanism of inhibition
of cell viability and proliferation. As cyclins/cyclin
dependent kinases tightly regulate the cell cycle progres-
sion [39,40], the effects of magnolol on cell cycle pro-
teins were investigated. Our findings revealed that
treatment of cells with magnolol resulted in a significant
decrease in cyclin A, cyclin B1, CDK2, CDK4, Cdc2 and
increase in Cip1/p21 expression at all concentrations
compared to control. Our studies on honokiol [17], an
isomer of magnolol have indicated similar anticarcino-
genic effects as magnolol. However, honokiol caused cell
cycle arrest at G0/G1 phase in A431 cells [41] unlike
magnolol which caused cell cycle arrest at G2/M phase.
Anticarcinogenic effects are modulated by two major
events: inhibition of cell proliferation and induction of
apoptosis [25,42]. Accordingly, the effects of magnolol
on induction of apoptosis in A431 cells were investi-
gated. During apoptosis, cells undergo changes such as
loss of phospholipids asymmetry of the plasma mem-
brane, cell shrinkage, proteases activation and finally
DNA fragmentation [43]. Our flow cytometry data
demonstrated that magnolol significantly induced
                      24 h                 48 h 
 Control      75        100      125     Control    75       100      125                Magnolol  concentration in M 
       1          0.87      0.75      0.6         1        0.74       1          0.25   
         p-STAT3 (Tyr 705) 
        1           0.96      1.14     1.72        1        0.67     0.47     0.68 
        p-STAT3 (Ser 727)  
          1             0.35    0.19     0.03             1           1     0.29       0                                                                         
       Cyclin D1                                           
        -Actin 
      1          0.8        0.8         0.9          1          1          0.8         0.23                 
         PCNA 
        -Actin 
Figure 9 Effects of magnolol on STAT3 phosphorylation in A431 cells. Sub confluent cells were treated with 0, 75, 100 and 125 μM of
magnolol for 24 and 48 h. At the end of each treatment, cells were harvested and total cell lysates were evaluated by Western blotting for
phosphorylation of STAT3 (Tyr 705 and Ser 727), PCNA and cyclin D1. Protein loading was verified by reprobing membrane for b-Actin.
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apoptosis in A431 cells as assessed by annexin-V/PI
staining which detects apoptotic cells by their loss of
phospholipids plasma membrane asymmetry. Then, later
we examined DNA fragmentation in apoptotic cell by
using TUNEL assay. Magnolol 48h treatment induced
DNA fragmentation in A431 cells at higher concentra-
tions (150 μM).
There are two reported pathways for the induction of
apoptosis. In the extrinsic or death receptor pathway of
apoptosis, activation of death receptors by ligands leads to
activation of caspase-8. This activated caspase-8 can acti-
vate caspase-3, an executioner caspase. Activated caspase-
3 can cleave PARP and thereby results in apoptosis
[44,45]. Consistent with the above reports, magnolol treat-
ment to A431 cells activated caspase-8 and caspase-3 in a
concentration dependent manner that led to PARP clea-
vage. These observations suggest that magnolol induced
apoptosis through extrinsic pathway and are consistent
with the results obtained from animal experiments.
The STAT pathway regulates the transcription of a
wide variety of genes involved in proliferation, develop-
ment, and tumorigenesis [46,47]. Among different
STAT family members, STAT3 is implicated in tumori-
genesis [47] and it plays an important role in skin can-
cer development [48]. STATs are activated either by
serine or tyrosine phosphorylation by JAK kinases, then
they undergo dimerization followed by nuclear translo-
cation and regulation of the expression of target genes
[49]. Our results showed that treatment of A431 cells
with magnolol inhibited the phosphorylation of STAT3
at tyrosine residues. Downstream targets of p-STAT3
include cyclin D1, our results showed that magnolol
decreased cyclin D1 expression, and this may lead to
cell cycle arrest [50]. In the present study, our in vitro
data has shown that magnolol treatment increased the
phosphorylation of ERK protein in A431 cells, suggest-
ing activation of ERK and upregulation of p21 by mag-
nolol as a mechanism for cell cycle arrest [51].
                  24 h                          48 h 
 Control     75        100        125       Control    75        100         125              Magnolol concentration in M
     1            1.5         0.44     0.59           1        0.92       0.59         0.7 
          B-Raf 
     1            0.64     0.47      0.29          1           1.4       0.69         0.5 
          p-MEK 
     1           0.39       0.59       4.8           1          0.75       2.16         1.5 
          p- ERK1/2 
          -Actin 
      1           0.4        0.34      0.43         1           0.8         0.54       0.56           
  p- AKT                         
 -Actin 
Figure 10 Effects of magnolol on B-Raf expression and MEK/ERK/AKT phosphorylation in A431 cells. Cells were treated with varying
concentrations of magnolol (0-125 μM) for 24 and 48 h. Cells were harvested and total cell lysates were prepared at the end of each treatment
and subjected to Western blot analysis for various proteins.
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However, further studies are needed to study the effects
of magnolol on the phosphorylation of these proteins at
very early stages instead of at 24h and 48h.
Magnolol inhibited cell proliferation through regula-
tion of Cip1/p21 in human glioblastoma cells [52],
induced apoptosis via inhibition of EGFR, PI3K/AKT
signaling pathways in human prostate cancer cells [36]
and inhibited MMP-9 expression through the transcrip-
tion factor NF-kB in TNF-a- induced human urinary
bladder cancer cells [53]. Magnolol induces apoptosis
via activation of both mitochondrial and death receptor
pathways in A375-S2 malignant melanoma cells [54].
Recent studies by Tanaka et al. [55], have shown the
preventive effects of magnolol on UV-induced photoa-
ging by inhibiting the expression of NF-kB. A recent
study by Kuo et al. [35] showed that magnolol down-
regulated TPA induced iNOS and COX-2 gene expres-
sion in mouse skin suggesting that magnolol could be
novel agent preventing inflammation associated
tumorigenesis.
Our studies for the first time provided the evidence
that magnolol pretreatment at very low doses (micro-
grams per applications compared to most other agents
which are used in milligrams per application) prevents
UVB-induced skin cancer development in SKH-1 mice
by both inducing apoptosis and decreasing cell prolifera-
tion through modulation of various signaling pathways.
The sunscreen effects of magnolol have not been inves-
tigated in this study which may contribute to anticarci-
nogenic effects. Future studies involving various
inhibitors, antisense oligonucleotides and dominant
negative mutants or siRNA are needed to map the path-
ways to conclude the signaling involved in the antican-
cer effects of magnolol. Magnolol has a great potential
to be a safe and potent chemopreventive agent against
skin cancer development in human.
Conclusions
Our studies for the first time provided the evidence that
magnolol pretreatment at very low doses (micrograms per
application compared to most other agents which are used
in milligrams per application) prevents UVB-induced skin
cancer development in SKH-1 mice both by inducing
apoptosis and decreasing cell proliferation through modu-
lation of various signaling pathways. Magnolol has a great
potential to be a safe and potent chemopreventive agent
against skin cancer development in human.
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